China may have signaled it's going more hard-line on trade, but it could be a good thing, former U.S. negotiator Clete Willems told CNBC.World Economyread more
As China's economic growth declines, some analysts say Beijing may have to spend more on infrastructure, adding to concerns about high debts.China Economyread more
After years of speculation, Neuralink, the brain-machine interface start-up co-founded by Elon Musk, started talking directly to the public on Tuesday.Technologyread more
"The charts, as interpreted by Carley Garner, suggest that the upside in the stock market has gotten more limited," Jim Cramer says.Mad Money with Jim Cramerread more
John Paul Stevens, who served on the Supreme Court for nearly 35 years and became its leading liberal, has died.Politicsread more
A key read on the industry, the Architecture Billings Index, fell into negative territory in June, according to the American Institute for Architects. Inquiries for new...Real Estateread more
The largest U.S. banks are scrutinizing members of the Federal Reserve for any insight into how the central bank will tinker interest rates.Banksread more
Mikaila Ulmer may be just 14 years old, but the Me & the Bees Lemonade founder knows a thing or two about business.Young Successread more
U.S. President Donald Trump said Tuesday that Washington and Beijing have a long way to go on trade, adding that America could place tariffs on an additional $325 billion...Asia Marketsread more
The U.S. and China restarted their trade talks, but signs are showing a comprehensive deal could be a long way off, if it happens at all.Marketsread more
The WTO ruling recognized that the United States had proved that China used state-owned enterprises to subsidize and distort its economy. But the U.S. must accept Chinese...World Economyread more
This arrangement, in which Ackman bought a 9.7 percent stake in the Botox maker at the behest of Valeant, was not front-running and not insider trading, Ackman said in a "Squawk Box " interview.
He said his lawyer—Robert Khuzami, former director of enforcement at the SEC—vetted the Valeant partnership and deemed it legal.
"The way the rules work is you're actually permitted to trade on inside information ... as long as you didn't receive the information from someone who breached … fiduciary duty or duty of confidentiality, et cetera," Ackman said.
"Valeant basically came to us and said, 'Look, if you can help us buy Allergan we can work with you.' We said, 'Great,' and we formed a partnership," he said. "The partnership has various terms. It gives us the right and permission from the company to go buy a stake in Allergan."
The founder of the Pershing Square Capital Management hedge fund—with $13 billion in assets under management—said he was not in the market buying Allergan stock before that.
Late Tuesday, Allergan adopted a poison pill—officially known as a shareholder rights plan—designed to prevent Ackman from acquiring more than his already-disclosed stake. In a statement, Allergan said it's trying to buy time as it considers whether accept, reject or negotiate the Ackman-Valeant bid.
Ackman told CNBC that Allergan's defensive move does not necessarily make the takeover more difficult. "If I were a director on this board, I would not immediately accept Valeant's proposal. They've hired Goldman Sachs and, I think, BofA. Those banks are going to reach out to other big pharma companies and potential buyers of the business. "
Also appearing on CNBC, Valeant Chairman and CEO J. Michael Pearson said he's "disappointed" Allergan adopted the poison pill, but he believes the deal will get done. "Having Bill out there in the public, he doesn't give up. We don't give up either. This helps the probability."
Ackman said his partnership with Valeant stipulates that Pershing will keep Allergan stock. "The reason Mike was willing to share with us the opportunity of Allergan is to help him buy Allergan. He doesn't need help our help buying Valeant," he said. "We put almost $4 billion in here."
Ackman said Valeant is more of a P&G than a Merck, and he likes Valeant's orientation toward consumer products, with brands like Bausch & Lomb contact lenses, rather toward health care.
Valeant first approached Allergan 18 months ago because Allergan has assets that will last a long time, said Pearson. "They have a great set of assets. What we look for in our business is durable assets ... that don't have big patent cliffs."
Early-stage science is not a good investment, said Pearson. "Most drugs get discovered by universities and entrepreneurs, not by large drug companies."
—By CNBC's Matthew J. Belvedere and Maneet Ahuja.